Growing Market Presence As part of Nexelis, AIT Bioscience benefits from the expanded reach and resources of a larger entity, positioning it well to attract clients seeking comprehensive bioanalytical services across various therapeutic areas and development stages.

Innovative Technology Portfolio AIT Bioscience offers advanced bioanalytical platforms like LC/MS and ligand binding, along with electronic lab notebooks, providing opportunities to upsell integrated testing services to pharmaceutical and biotech sponsors prioritizing cutting-edge solutions.

Recent Asset Investments Nexelis's recent acquisitions of GCLP-certified laboratories indicate a focus on high-quality, compliant facilities, which can appeal to clients with strict regulatory needs and enhance the company’s credibility in bioanalytical testing.

Strategic Growth Backing Backed by Ampersand Capital and with an established growth strategy, Nexelis and AIT Bioscience are positioned to expand their customer base through targeted outreach to innovative biotech firms and pharma companies investing in early and late-stage development.

Scope for Mid-Sized Engagements With a relatively modest employee count and revenue in the $10M-$25M range, there are significant opportunities to tailor services and grow relationships with mid-sized biotech and pharmaceutical companies seeking flexible, cost-effective bioanalytical solutions.